[ad_1]
SINGAPORE: Singapore reported nine new COVID-19 cases as of noon on Thursday (December 3), including a locally transmitted infection.
The local case is a one bedroom resident and was asymptomatic. The man, known as Case 58443, was detected through surveillance, reported the Ministry of Health (MINSA).
“His polymerase chain reaction test returned a very high Ct (cycle threshold) value, indicating a low viral load. All of his close contacts in the bedroom and at his workplace have been isolated and quarantined. “added the ministry.
The rest of the infections are imported cases and were placed on admission notice upon arrival in Singapore. All were asymptomatic.
READ: HSA Evaluates Initial COVID-19 Vaccine Data Submitted by Moderna for Use in Singapore
The imported cases include a Singaporean and two permanent residents who returned from the United States. Two other cases are job pass holders currently employed in Singapore who came from Nepal.
The remaining cases include a dependent’s pass holder who arrived from France and two short-term visit pass holders who arrived from Indonesia: one to visit relatives from Singapore and the other to visit her fiancé.
There were no new cases in the community.
The Health Ministry said that the total number of new cases in the community has remained low, with a total of four cases in the last week that are currently not linked. More details can be found in the daily situation report of the Ministry of Health.
A LOWER PATIENT
One more case was discharged from the hospital, bringing Singapore’s total recoveries to 58,145.
There are 26 cases still in the hospital. Most of them are stable or improving and no one is in the intensive care unit. Another 39 are being isolated and cared for in community facilities.
Twenty-nine people died of complications due to COVID-19 infection.
As of Thursday, Singapore has reported a total of 58,839 COVID-19 cases.
HSA EVALUATING DATA ON THE COVID-19 VACCINE PRESENTED BY MODERNA
Moderna has begun submitting initial data about its COVID-19 vaccine candidate to the Health Sciences Authority (HSA), the authority said Wednesday.
This is part of the process to assess its suitability for use in Singapore.
The biotech company “will continue to enter data as soon as it becomes available,” as agreed with the authority, HSA said.
A rolling review process, or rolling submission, allows companies to submit real-time data from ongoing vaccine studies while the regulatory review is taking place simultaneously.
HSA said it has already begun evaluating the available data submitted by Moderna to ensure a “quick review.”
On Monday, Moderna announced that it was “moving forward” with the ongoing review process for approval with the HSA.
Moderna said its vaccine was 94.1 percent effective against COVID-19 and 100 percent effective in preventing severe cases following the results of a late-stage phase 3 study.
CHECK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
